mardi 8 octobre 2019

Johnson & Johnson Hit With $8 Billion Jury Verdict in Risperdal Suit

A Philadelphia jury found that a subsidiary downplayed the risks that the anti-psychotic drug could lead to breast growth in boys.

from NYT > Health https://ift.tt/33j2SNI
via health&fitness

Aucun commentaire:

Enregistrer un commentaire